All In MedTech

FDA Clearance Tracker · P170043-S007

iStent inject Trabecular Micro-Bypass System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 30, 2020 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 30, 2020

Approved

Time to decision

58 days

Received Mar 3, 2020. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P170043-S007
Device name
iStent inject Trabecular Micro-Bypass System
Applicant location
San Clemente, CA
Received
Mar 3, 2020
Decided
Apr 30, 2020
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P170043

Device type

Device class
Class III
Specialty
Ophthalmology

Every decision under product code OGO

FDA's approval statement

As written in FDA's record.

Approval of the revised protocol for the post-approval study (PAS) protocol.

Source documents

Other decisions for Glaukos Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

1 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.